The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
A prospective, randomised, controlled, multi‐centre comparative effectiveness study of healing using dehydrated human amnion/chorion membrane allograft, bioengineered skin substitute or standard of care for treatment of chronic lower extremity diabetic ulcers
Abstract
A prospective, randomised, controlled, parallel group, multi‐centre clinical trial was conducted at three sites to compare the healing effectiveness of treatment of chronic lower extremity diabetic ulcers with either weekly applications of Apligraf ® (Organogenesis, Inc., Canton, MA ), EpiFix ® ( MiMedx Group, Inc., Marietta, GA ), or standard wound care with collagen‐alginate dressing. The primary study outcome was the percent change in complete wound healing after 4 and 6 weeks of treatment. Secondary outcomes included percent change in wound area per week, velocity of wound closure and a calculation of the amount and cost of Apligraf or EpiFix used . A total of 65 subjects entered the 2‐week run‐in period and 60 were randomised (20 per group). The proportion of patients in the EpiFix group achieving complete wound closure within 4 and 6 weeks was 85% and 95%, significantly higher (all adjusted P ‐values ≤ 0·003) than for patients receiving Apligraf (35% and 45%), or standard care (30% and 35%). After 1 week, wounds treated with EpiFix had reduced in area by 83·5% compared with 53·1% for wounds treated with Apligraf. Median time to healing was significantly faster (all adjusted P ‐values ≤0·001) with EpiFix (13 days) compared to Apligraf (49 days) or standard care (49 days). The mean number of grafts used and the graft cost per patient were lower in the EpiFix group campared to the Apligraf group, at 2·15 grafts at a cost of $1669 versus 6·2 grafts at a cost of $9216, respectively. The results of this study demonstrate the clinical and resource utilisation superiority of EpiFix compared to Apligraf or standard of care, for the treatment of diabetic ulcers of the lower extremities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cellular dermal matrix is usually made up of extracellular matrix, viable cells, growth factors, etc [10,37,38].”
From Efficacy and safety of acellular dermal matrix in diabetic foot ulcer treatment: A systematic review and meta-analysis (2017) · cites this paper as [10]
In the citing paper
“The reported healing rate using ADM could be up to 80% at 12 weeks [10].”
From Efficacy and safety of acellular dermal matrix in diabetic foot ulcer treatment: A systematic review and meta-analysis (2017) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Economic Costs of Diabetes in the U.S. in 2002
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.3.917 · Cited by 4,147
Research works printed but not linked: 31
- 10.1016/j.diabres.2009.10.007 · DOI · Paper page
- 10.2337/dc12-2625 · DOI
- 10.2337/dc08-9021 · DOI
- Driver VR, 2008, Health economic implications for wound care and limb preservation, J Manag Care Med, 11, 13
- Snyder R, 2010, Wound percent area reduction and making decisions about utilizing advanced therapies, Podiatry Manage, 29, 197
- 10.1111/j.1524-475X.2006.00176.x · DOI · Paper page
- 10.1016/S0891-8422(02)00018-6 · DOI
- HoC TranK HuxM SibbaldG CampbellK.Artificial skin grafts in chronic wound care: a meta‐analysis of clinical efficacy and a review of cost‐effectiveness[Tech. Rep. No. 52]. Ottawa: Canadian Coordinating Office for Health Technology Assessment 2005.
- 10.2337/diacare.24.2.290 · DOI · Paper page
- 10.2337/diacare.26.6.1701 · DOI · Paper page
- 10.1111/iwj.12097 · DOI
- Fetterolf DE, 2014, An evaluation of healing metrics associated with commonly used advanced wound care products for the treatment of chronic diabetic foot ulcers, Manag Care, 23, 31
- 10.1111/iwj.12140 · DOI · Paper page
- 10.1016/j.jss.2014.08.045 · DOI
- 10.12968/jowc.2013.22.7.347 · DOI
- 10.1111/iwj.12242 · DOI
- 10.1097/01.ASW.0000288217.83128.f3 · DOI
- 10.1111/j.1524-475X.2011.00673.x · DOI · Paper page
- 10.1097/00129334-200511000-00013 · DOI
- 10.1111/wrr.12154 · DOI
- Brem H, 2003, Clinical efficacy and mechanism of bilayered living human skin equivalent (HSE) in treatment of diabetic foot ulcers, Surg Technol Int, 11, 23
- 10.1046/j.1365-2133.2002.04563.x · DOI
- 10.1016/S0896-1549(02)00110-4 · DOI
- 10.22203/eCM.v015a07 · DOI
- 10.1002/jbm.b.33141 · DOI
- Chen Z, 2014, Therapeutic implications of newly identified stem cell populations from the skin dermis, Cell Transplant
- 10.1016/j.trsl.2013.11.009 · DOI
- 10.1172/JCI29710 · DOI · Paper page
- 10.1016/j.jss.2007.03.051 · DOI
- 10.1002/jbm.b.33265 · DOI
- 10.1186/1472-6963-9-115 · DOI
Cited by
Chen, P., Vilorio, N. C., Dhatariya, K., Jeffcoate, W., Lobmann, R., McIntosh, C., Piaggesi, A., Steinberg, J., Vas, P., Viswanathan, V., et al. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3644 · Cited by 246
“223 Of these, one described the use of dehydrated amnion/chorion graft, 221 seven used dehydrated human amniotic membrane (dHAM), 153,203,216,218,219,222,223 one the use of cryopreserved placental membrane, 217 and one the use of dehydrated human umbilical cord.”
BackgroundThe Tumor Microenvironment in Tumorigenesis and Therapy Resistance Revisited
Dzobo, K., Senthebane, D. A., & Dandara, C. (2023) · Cancers · doi:10.3390/cancers15020376 · Cited by 146
Guo, X., Mu, D., & Gao, F. (2017) · International Journal of Surgery · doi:10.1016/j.ijsu.2017.02.008 · Cited by 80
Extracellular matrix-inspired biomaterials for wound healing
Hosty, L., Heatherington, T., Quondamatteo, F., & Browne, S. (2024) · Molecular Biology Reports · doi:10.1007/s11033-024-09750-9 · Cited by 63
Mohammed, Y. A., Farouk, H. K., Gbreel, M. I., Ali, A. M., Salah, A. A., Nourelden, A. Z., & Gawad, M. M. A. (2022) · Journal of Foot and Ankle Research · doi:10.1186/s13047-022-00575-y · Cited by 36
Metadata
- Authors
- Zelen, C. M., Gould, L., Serena, T. E., Carter, M. J., Keller, J., & Li, W. W.
- Venue
- International Wound Journal
- Publisher
- Wiley
- Published
- 2014-11-26
- Volume
- 12
- Issue
- 6
- Pages
- 724-732
- ISSN
- 1742-4801
- 1742-481X
- Cited by
- 165
- References
- 1
- Language
- en
- Funders
- MiMedx Group, Inc.
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
